NRX Pharmaceuticals, Inc.

Name: NRX Pharmaceuticals, Inc. standardized financial statements, quarterly
Creator: Listed

NRXPNasdaqCIK 1719406HealthcareFiscal year ends Dec 31

Share this page

Link

Story card, 1080 × 1920

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Revenue$1.1m, Q2 FY2026

Operating income−$6.5m, Q2 FY2026

Net income−$16.5m, Q2 FY2026

NRX Pharmaceuticals, Inc., income statement, quarterly
Line item	Unit	Q3 FY20232023-09-30	Q4 FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q4 FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q4 FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Revenue	$m	not reported	not reported	not reported	not reported	0.0	0.0	0.0	0.0	0.2	1.0	1.1	1.1
Cost of revenue	$m	not reported	not reported	not reported	not reported	0.0	0.0	0.0	0.0	0.1	0.4	0.6	0.7
Research and development	$m	3.3	2.5	1.7	2.8	0.6	1.0	0.8	1.0	1.4	0.6	1.3	2.1
Selling, general and administrative	$m	not reported	not reported	not reported	not reported	2.4	2.6	2.9	2.7	2.8	4.6	3.8	4.7
Operating income	$m	(5.8)	(4.4)	(6.0)	(7.1)	(3.0)	(2.4)	(3.8)	(3.7)	(4.0)	(4.6)	(4.7)	(6.5)
Interest expense	$m	0.0	0.1	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.2	0.2
Income tax	$m	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Net income	$m	(6.1)	(4.3)	(6.5)	(7.9)	(1.6)	(9.1)	(5.5)	(17.6)	(5.9)	0.4	(1.4)	(16.5)
Diluted EPS	$ per share	(0.07)	not reported	(0.74)	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported
Basic EPS	$ per share	(0.74)	not reported	(0.74)	(0.75)	(0.15)	not reported	(0.34)	(0.98)	(0.27)	not reported	(0.04)	(0.44)

Balance sheet

Cash and equivalents$26.7m, Q2 FY2026

Long-term debt$9.2m, FY2023

Shareholders' equity−$170.0k, Q2 FY2026

NRX Pharmaceuticals, Inc., balance sheet, quarterly
Line item	Unit	Q3 FY20232023-09-30	FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Cash and equivalents	$m	8.9	4.6	1.3	1.9	1.6	1.4	5.5	2.9	7.2	7.8	6.7	26.7
Current assets	$m	13.1	6.9	3.3	4.9	4.1	3.3	7.3	4.6	11.9	8.9	7.4	29.2
Total assets	$m	13.1	7.3	3.8	5.3	4.5	3.7	7.6	4.8	15.0	13.0	11.9	34.2
Current liabilities	$m	19.3	19.0	not reported	not reported	20.3	21.9	32.8	40.5	40.6	28.6	25.2	33.9
Total liabilities	$m	19.3	19.0	18.9	23.7	23.3	26.9	32.8	40.5	40.8	28.9	25.7	34.3
Long-term debt	$m	10.1	9.2	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported
Current portion of debt	$m	10.1	9.2	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported
Shareholders' equity	$m	(6.2)	(11.7)	(15.1)	(18.4)	(18.8)	(23.2)	(25.2)	(35.6)	(25.8)	(15.9)	(13.8)	(0.2)

Cash flow

Operating cash flow−$8.9m, Q2 FY2026

Capital expenditure$0, Q2 FY2025

NRX Pharmaceuticals, Inc., cash flow, quarterly
Line item	Unit	Q3 FY20232023-09-30	Q4 FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q4 FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q4 FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Operating cash flow	$k	(4,564)	(3,192)	(3,671)	(2,562)	(2,306)	(2,098)	(3,480)	(4,028)	(2,891)	(3,713)	(4,295)	(8,875)
Capital expenditure	$k	2.0	(1.0)	0.0	0.0	0.0	0.0	0.0	0.0	not reported	not reported	not reported	not reported
Share repurchases	$k	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported

Diluted shares (weighted)8.85m, Q1 FY2024

NRX Pharmaceuticals, Inc., shares, quarterly
Line item	Unit	Q2 FY20202020-06-30	Q3 FY20202020-09-30	Q1 FY20212021-03-31	Q2 FY20212021-06-30	Q3 FY20212021-09-30	Q1 FY20222022-03-31	Q2 FY20222022-06-30	Q3 FY20222022-09-30	Q1 FY20232023-03-31	Q2 FY20232023-06-30	Q3 FY20232023-09-30	Q1 FY20242024-03-31
Diluted shares (weighted)	m shares	36.7	34.1	35.7	42.5	51.7	63.7	65.7	66.4	6.6	73.2	81.9	8.9

Shares outstanding: 43.30m at Aug 14, 2026, from the cover of the 10-Q filed Aug 14, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:46 ET. Listed shows no prices and gives no investment advice.